As scientists we have learned that neurodegenerative disorders need a new form of treatment, as the existing treatments have a higher rate of failure. For the past 20 years we have had a different notion on neurodegenerative disorders, it's time to rethink the way we treat them and to innovate in this area, that is why we want to bring new forms of treatment to the society.
We want to help improve and democratize mental health treatments
This is why we founded Actipulse Neuroscience®

We are a neuro-tech company specialized in the research and engineering of Non-Invasive Brain Stimulation technologies for the treatment of psychiatric and neurological disorders.

We are pioneers in Non-Invasive Brain Stimulation technologies with a particular focus on transcranial neuromodulation devices using high frequency magnetic pulses that target multiple well known, but neglected pathogenic mechanisms in neurodegenerative disorders.

Current Clinical Pipeline

Actipulse Neuroscience is focused on leading world class research with a particular emphasis on respecting the highest clinical and ethical standards.

  • Major Depressive Disorder

    PLANNED

    FUNCTIONAL PROTOTYPE

    PROOF OF CONCEPT STUDY

    PILOT STUDY

    PIVOTAL STUDY =n240

    Anticipated start of next milestone: Q1 2022

    • Tobacco Addiction

      PLANNED

      FUNCTIONAL PROTOTYPE

      PROOF OF CONCEPT STUDY

      PILOT STUDY = n50

      Anticipated start of next milestone: Q1 2022

    • Alzheimer’s Disease

      PLANNED

      FUNCTIONAL PROTOTYPE

      PROOF OF CONCEPT STUDY

      PILOT STUDY = n30

      Anticipated start of next milestone: Q1 2022

    • Parkinson’s Disease

      PLANNED

      Anticipated start of next milestone: Q1 2022

    • CNC3

      PLANNED

      Anticipated start of next milestone: Q1 2022

    • CNC4

      PLANNED

      Anticipated start of next milestone: Q4 2022

The future golden standard of neurodegenerative treatment

Actipulse Neuroscience has for goal to be the golden standard of neuromodulation technologies in the next five years and to become an integral part of the treatment of the millions of patients suffering from Parkinson’s Disease and dementia in the world.

Contact us
For Investor Relations inquiries

Please email:
adrien.chatillon@actipulse.com

Actipulse Neuroscience, Inc.

Global Headquarters
210 Broadway,
Cambridge, MA

Actipulse International SA de CV

Latin America HQ
Nuevo Leon 202
Mexico City

Actipulse Chile SRL

South America HQ
Av. Nueva Providencia, 1881
Santiago de Chile